Harfst & Associates Inc. Makes New Investment in Danaher Corporation (NYSE:DHR)

Harfst & Associates Inc. bought a new position in Danaher Corporation (NYSE:DHR) in the 1st quarter, HoldingsChannel.com reports. The fund bought 3,298 shares of the conglomerate’s stock, valued at approximately $676,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Heck Capital Advisors LLC bought a new stake in Danaher in the fourth quarter valued at approximately $27,000. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Sierra Ocean LLC lifted its position in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in Danaher in the first quarter valued at approximately $31,000. Finally, Dunhill Financial LLC lifted its position in Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on DHR. UBS Group lowered their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. HSBC lowered their price objective on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Evercore ISI decreased their target price on Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Robert W. Baird upped their target price on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a report on Friday, July 18th. Finally, Barclays restated an “overweight” rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $247.61.

Danaher Price Performance

Shares of DHR stock opened at $209.28 on Thursday. The stock has a market cap of $149.85 billion, a price-to-earnings ratio of 44.53, a PEG ratio of 2.87 and a beta of 0.73. The business’s fifty day moving average is $199.27 and its 200 day moving average is $200.40. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same period in the prior year, the firm earned $1.72 earnings per share. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. Research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.